Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for KIMMTRAK (Tebentafusp) +/- anti-PD1 in Cancer, Melanoma. The expected timing is based on the latest available company guidance and may change.
TEBE-AM trial. 02/28/24- Enrollment ongoing. 5/29/24- Converted into Ph3 trial. 2/26/25- Trial ongoing. Complete enrollment in H1 2026 w/ data in 2026. 11/06/25:- TEBE-AM Ph3 trial enrollment ongoing; company expects enrollment completion in H1 2026. 02/25/26:- TEBE-AM Ph3 2L+ CM trial enrollment completion still expected H1 2026; topline OS data as early as 2H 2026. 05/06/26:- TEBE-AM Ph3 2L+ CM trial enrollment ongoing; completion still H1 2026, topline OS data as early as 2H 2026. 08/06/26:- TEBE-AM enrollment nearing 540-patient target; topline data could come end 2026.
Verification
Confirm timing and program details against the company announcement or filing.